KR20230017843A - 폐 섬유증을 치료하는 방법 - Google Patents

폐 섬유증을 치료하는 방법 Download PDF

Info

Publication number
KR20230017843A
KR20230017843A KR1020227045766A KR20227045766A KR20230017843A KR 20230017843 A KR20230017843 A KR 20230017843A KR 1020227045766 A KR1020227045766 A KR 1020227045766A KR 20227045766 A KR20227045766 A KR 20227045766A KR 20230017843 A KR20230017843 A KR 20230017843A
Authority
KR
South Korea
Prior art keywords
formula
pulmonary fibrosis
acid
compound
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227045766A
Other languages
English (en)
Korean (ko)
Inventor
크리스 번즈
존 램버트
마크 그레이엄 데브린
Original Assignee
앰플리아 테라퓨틱스 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901743A external-priority patent/AU2020901743A0/en
Application filed by 앰플리아 테라퓨틱스 피티와이 엘티디 filed Critical 앰플리아 테라퓨틱스 피티와이 엘티디
Publication of KR20230017843A publication Critical patent/KR20230017843A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227045766A 2020-05-28 2021-05-17 폐 섬유증을 치료하는 방법 Pending KR20230017843A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901743 2020-05-28
AU2020901743A AU2020901743A0 (en) 2020-05-28 Methods of treating pulmonary fibrosis
PCT/AU2021/050457 WO2021237273A1 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
KR20230017843A true KR20230017843A (ko) 2023-02-06

Family

ID=78745664

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045766A Pending KR20230017843A (ko) 2020-05-28 2021-05-17 폐 섬유증을 치료하는 방법

Country Status (9)

Country Link
US (1) US20230190746A1 (https=)
EP (1) EP4157278A4 (https=)
JP (1) JP7745571B2 (https=)
KR (1) KR20230017843A (https=)
CN (1) CN115867281A (https=)
AU (1) AU2021279205B2 (https=)
CA (1) CA3177652A1 (https=)
NZ (1) NZ793855A (https=)
WO (1) WO2021237273A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3001119T3 (es) 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK
WO2023139154A1 (en) * 2022-01-19 2023-07-27 Nordic Bioscience A/S A method for detecting covid-19 in a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174946B2 (en) * 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
ES3001119T3 (es) * 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK

Also Published As

Publication number Publication date
JP7745571B2 (ja) 2025-09-29
US20230190746A1 (en) 2023-06-22
WO2021237273A1 (en) 2021-12-02
NZ793855A (en) 2026-02-27
CN115867281A (zh) 2023-03-28
EP4157278A4 (en) 2024-07-03
EP4157278A1 (en) 2023-04-05
AU2021279205A1 (en) 2022-12-08
JP2023527358A (ja) 2023-06-28
AU2021279205B2 (en) 2025-12-04
CA3177652A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
EP2968208B1 (en) Treatment of cataplexy
US8642600B2 (en) Method of treating autism
EP3925959A1 (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
US20090023712A1 (en) Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
KR20090024281A (ko) 다발성 경화증 치료용 ｓ１ｐ 수용체 조절제
US20060258712A1 (en) Methods for modulating bladder function
JP2010514696A (ja) 心血管症状の低減
CN107847480A (zh) 呼吸性疾病的治疗
WO2019160057A1 (ja) 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN1270708C (zh) 间质性膀胱炎治疗用医药组合物
US20130079304A1 (en) Pharmaceutical Compositions for the Treatment of Fungal Infections
KR20230017843A (ko) 폐 섬유증을 치료하는 방법
EP2172201A1 (en) Pharmaceutical composition for amelioration of lower urinary tract symptom associated with prostatomegaly
TW201707708A (zh) 選擇性黃體酮受體調節劑（ｓｐｒｍ）療法
CN105813642A (zh) Par-1拮抗剂用于预防和/或治疗骨盆-会阴功能病状的用途
KR20190013847A (ko) 불안 장애를 치료하기 위한 (2S)-1-[4-(3,4-디클로로페닐)피페리딘-1-일]-3-[2-(5-메틸-1,3,4-옥사디아졸-2-일)벤조[b]푸란-4-일옥시]프로판-2-올 또는 그의 대사산물
US20090247585A1 (en) Pharmaceutical composition comprising, in combination, saredutant and escitalopram
JP2023537418A (ja) 慢性腎症を治療する方法及び医薬組成物
US20230108050A1 (en) Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
JP2026510948A (ja) 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法
US20040006142A1 (en) Ocular tension depressor
TW202045184A (zh) 預防或治療肺纖維化的藥物
HK1221913B (zh) Par-1拮抗剂用於预防和/或治疗骨盆-会阴功能病状的用途
EP0998923A1 (en) Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902